Financial News

Apricus Biosciences Confirms Clinical Strategy for Novel Treatment for Symptomatic Secondary Hypogonadism Fispemifene

By: via Benzinga
Apricus Biosciences, Inc. (Nasdaq: APRI) today reaffirmed its regulatory and clinical strategy for the development of fispemifene in ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback